Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PT at $56.33

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $56.57.

AGIO has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Scotiabank lifted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. HC Wainwright started coverage on Agios Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $58.00 price objective on the stock. Finally, Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning lifted its position in shares of Agios Pharmaceuticals by 35.8% in the third quarter. Creative Planning now owns 15,640 shares of the biopharmaceutical company’s stock valued at $695,000 after acquiring an additional 4,120 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 363 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,942 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 4,272 shares in the last quarter. Oak Ridge Investments LLC lifted its position in shares of Agios Pharmaceuticals by 14.6% in the third quarter. Oak Ridge Investments LLC now owns 40,378 shares of the biopharmaceutical company’s stock worth $1,794,000 after buying an additional 5,142 shares in the last quarter. Finally, Harbor Capital Advisors Inc. increased its stake in Agios Pharmaceuticals by 19.3% during the third quarter. Harbor Capital Advisors Inc. now owns 39,090 shares of the biopharmaceutical company’s stock worth $1,737,000 after acquiring an additional 6,320 shares during the last quarter.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $34.44 on Monday. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 3.04 and a beta of 0.88. The business has a 50-day moving average of $33.92 and a 200-day moving average of $42.86. Agios Pharmaceuticals has a 1 year low of $27.14 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, sell-side analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.